A Phase 1b, Double-Blind, Randomized, Dose-Escalating, Age De-Escalating, Placebo-Controlled Study to Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine Delivered Intranasally In a Healthy Pediatric Population 6 Months Through 17 Years of Age.

  • STATUS
    Recruiting
  • End date
    Nov 1, 2023
  • participants needed
    200
  • sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
Updated on 29 October 2022
Investigator
James Campbell
Primary Contact
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore (7.7 mi away) Contact
+3 other location
Accepts healthy volunteers

Summary

This is a Phase 1b, randomized, double-blind, dose-escalating, age de-escalating, placebo-controlled study of 200 children, ages 6 months to 17 years. This clinical trial is designed to assess the safety, tolerability/reactogenicity, and immunogenicity of one and two doses of Sing2016 M2SR H3N2 influenza vaccine (manufactured by FluGen) administered intranasally in seven cohorts of children.

The first two groups to be vaccinated will be Cohorts 1 and 2. Cohort 1 consists of 45 children 9-17 years old. Thirty of them will receive one dose of the vaccine at a dose of 10^9 TCID50, and 15 will receive one dose of placebo. Cohort 2 comprises 45 children 2-8 years old. Thirty of them will receive one dose of the vaccine at a dose of 10^8 TCID50 and 15 will receive one dose of placebo.

Cohort 3 consists of 25 children 2-8 years old. 15 of them will receive one dose of vaccine at 10^9 TCID50 and 10 will receive one dose of placebo. Once 25 participants in Cohort 3 have completed Day 8 of follow-up, similar to Cohorts 1 and 2, the SRC will review to ensure no halting rules are met and if no rules are met, and the SRC determines it is safe to proceed, simultaneous enrollment into Cohorts 4 and 5 can begin. If any halting rules are met or any concerns are raised by the SRC, an external SMC may meet to discuss the data for recommendations on either progression or clinical trial modification before progression to the next cohort.

Cohort 4 consists of 25 children 2-8 years old; 15 of them will receive two doses of vaccine at 10^9 TCID50 and 10 will receive two doses of placebo, with a 28-day interval between the first and second doses. Cohort 5 will enroll 8 influenza naïve children (defined as children without receipt of influenza vaccine and without previous documented influenza infection) who are 6-23 mo who will be randomly assigned to receive two doses of 10^7 TCID50 Sing2016 M2SR (n=6) or two doses of placebo (n=2) with a 28-day interval between the first and second dose. Once all 25 participants in Cohort 4 and all 8 of Cohort 5 have completed Day 36 of follow-up, the SRC will conduct a safety assessment to begin enrollment in Cohort 6.

Cohorts 6 and 7 will also enroll 6- to 23-month-olds who are influenza-naïve. Cohort 6 will consist of 26 children. A lead-in group of 8 children will be randomly assigned to receive either two doses of 10^8 TCID50 of the Sing2016 M2SR (n=6) or two doses of placebo (n=2). Once the first 8 children have completed Day 8 (8 days after first dose), the SRC will review the safety and determine if Cohort 7 may open to enrollment. Cohort 7 enrollment will not begin until Cohort 6 is fully enrolled. Similar to other cohorts, the additional 18 children in Cohort 6 may continue to enroll during the SRC review.

Cohort 7 will be the final cohort. Twenty-six children will be randomly allocated to receive two doses of either 10^9 TCID50 Sing2016 M2SR (n=18) or placebo (n=8). This cohort does not have a "lead-in" group since data from such a group are not needed to allow the enrollment in a subsequent cohort. However, the study-wide and individual halting rules still apply.

The primary study objective is to assess the safety and tolerability of one and two administrations of the Sing2016 M2SR H3N2 influenza vaccine at 10^7, 10^8, or 10^9 TCID50 delivered intranasally to healthy participants, 6 months to 17 years of age

Description

This is a Phase 1b, randomized, double-blind, dose-escalating, age de-escalating, placebo-controlled study of 200 children, ages 6 months to 17 years. This clinical trial is designed to assess the safety, tolerability/reactogenicity, and immunogenicity of one and two doses of Sing2016 M2SR H3N2 influenza vaccine (manufactured by FluGen) administered intranasally in seven cohorts of children.

The first two groups to be vaccinated will be Cohorts 1 and 2. Cohort 1 consists of 45 children 9-17 years old. Thirty of them will receive one dose of the vaccine at a dose of 10^9 TCID50, and 15 will receive one dose of placebo. Cohort 2 comprises 45 children 2-8 years old. Thirty of them will receive one dose of the vaccine at a dose of 10^8 TCID50 and 15 will receive one dose of placebo. Sites will enroll participants into Cohorts 1 and 2 simultaneously. Once 25 or more participants in each of the first 2 cohorts (Cohorts 1 and 2) have completed Day 8, SRC will evaluate if any halting rules are met and if it is deemed safe enrollment in Cohort 3 may open. Cohort 2 must fully enroll before enrollment in Cohort 3 may begin.

Cohort 3 consists of 25 children 2-8 years old. 15 of them will receive one dose of vaccine at 10^9 TCID50 and 10 will receive one dose of placebo. Once 25 participants in Cohort 3 have completed Day 8 of follow-up, similar to Cohorts 1 and 2, the SRC will review to ensure no halting rules are met and if no rules are met, and the SRC determines it is safe to proceed, simultaneous enrollment into Cohorts 4 and 5 can begin. If any halting rules are met or any concerns are raised by the SRC, an external SMC may meet to discuss the data for recommendations on either progression or clinical trial modification before progression to the next cohort.

Cohort 4 consists of 25 children 2-8 years old; 15 of them will receive two doses of vaccine at 10^9 TCID50 and 10 will receive two doses of placebo, with a 28-day interval between the first and second doses. Cohort 5 will enroll 8 influenza naïve children (defined as children without receipt of influenza vaccine and without previous documented influenza infection) who are 6-23 mo who will be randomly assigned to receive two doses of 10^7 TCID50 Sing2016 M2SR (n=6) or two doses of placebo (n=2) with a 28-day interval between the first and second dose. Once all 25 participants in Cohort 4 and all 8 of Cohort 5 have completed Day 36 of follow-up, the SRC will conduct a safety assessment to begin enrollment in Cohort 6.

Cohorts 6 and 7 will also enroll 6- to 23-month-olds who are influenza-naïve. Cohort 6 will consist of 26 children. A lead-in group of 8 children will be randomly assigned to receive either two doses of 10^8 TCID50 of the Sing2016 M2SR (n=6) or two doses of placebo (n=2). Once the first 8 children have completed Day 8 (8 days after first dose), the SRC will review the safety and determine if Cohort 7 may open to enrollment. Cohort 7 enrollment will not begin until Cohort 6 is fully enrolled. Similar to other cohorts, the additional 18 children in Cohort 6 may continue to enroll during the SRC review.

Cohort 7 will be the final cohort. Twenty-six children will be randomly allocated to receive two doses of either 10^9 TCID50 Sing2016 M2SR (n=18) or placebo (n=8). This cohort does not have a "lead-in" group since data from such a group are not needed to allow the enrollment in a subsequent cohort. However, the study-wide and individual halting rules still apply.

The primary study objective is to assess the safety and tolerability of one and two administrations of the Sing2016 M2SR H3N2 influenza vaccine at 10^7, 10^8, or 10^9 TCID50 delivered intranasally to healthy participants, 6 months to 17 years of age. The secondary study objective is to assess the humoral immunogenicity (serum antibody and mucosal antibody responses) directed against homologous viral strains after one and two administrations of Sing2016 M2SR H3N2 influenza vaccine at 10^7, 10^8, or 10^9 TCID50 delivered intranasally to healthy participants, 6 months to 17 years of age

Details
Condition H3N2 Influenza
Treatment Placebo, Sing2016 M2SR H3N2
Clinical Study IdentifierNCT04960397
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on29 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant is a male or female child aged 6 months to 17 years inclusive at time of enrollment (each cohort has its own age upper and lower limits)
Cohort 1: 9-17 years (on or after the ninth birthday and before the eighteenth birthday at the time of the first dose); Cohorts 2, 3, and 4: 2-8 years (on or after the second birthday and before the ninth birthday at the time of the first dose); Cohorts 5, 6, and 7: 6 months to 23 months (on or after the sixth month of life based on calendar day and before the second birthday at the time of the first dose) 2. For Cohorts 1 to 4, receipt of at least 2 doses of seasonal influenza vaccine in the past. 3. For Cohorts 5 to 7, receipt of no seasonal influenza vaccines in the past and no documented history of laboratory-confirmed influenza illness 4. Parent/guardian of the participating child provides written informed permission and participating child provides assent prior to initiation of any study procedures
As appropriate by age or development and approved by the Institutional Review Board (IRB) 5. Parent/guardian and participant, as appropriate, are able to understand and comply with planned study procedures and are available for all study visits 6. Participant is in good health as assessed by the principal investigator or other designated study investigator
Based on medical history and physical examination (physical examination may be done as part of routine medical care or specifically for eligibility screening) 7. Parent/guardian of the participating child agrees not to allow the participant to join another clinical trial that includes an investigational agent or device during the study period 8. A female participant of child-bearing potential _agrees to abstain from sexual intercourse or to correctly use an acceptable method of contraception_
A female of child-bearing potential is defined as a female who is post-menarchal and not sterilized via tubal ligation, bilateral oophorectomy, salpingectomy, hysterectomy, or successful Essure (R) placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure. This applies only to participants in Cohort 1
Acceptable methods of contraception must be used from 30 days prior to
vaccination until 60 days after the last study vaccination (not Inactivated
Influenza Vaccine (IIV4)) and include full abstinence from sexual intercourse
with a male partner, monogamous relationship with vasectomized partner who has
been vasectomized for 180 days or more or shown to be azoospermic prior to the
participant receiving the study vaccination, barrier methods such as condoms
or diaphragms/cervical cap, intrauterine devices, NuvaRing (R), and licensed
hormonal methods such as implants, injectables, or oral contraceptives ("the
pill")
\. A female participant of child-bearing potential must have a negative urine
pregnancy test within 24 hours prior to each study product 10. A male who is
sexually active with a female of childbearing potential must agree to use an
acceptable method of contraception
From the time of the first dose of study vaccine until 60 days after receipt of the last dose study vaccine, only in cohort 1. The only acceptable method of contraception for males who are sexually active with females of childbearing potential is condoms

Exclusion Criteria

Has a body temperature of 38 degrees Celsius or 100.4 degrees Fahrenheit (oral or axillary) or greater or another acute illness within the 72 hours prior to study vaccination
Potential participants who are recovering from an acute illness and have residual minimal symptoms, which, in the opinion of the site principal investigator or appropriate sub-investigator, will not likely affect the evaluation of outcome measures are not ineligible. Temperature evaluation will not be performed as a study procedure on participants prior to administration of seasonal influenza vaccine
Has any medical or mental health disease or condition that would render study participation unsafe, or would interfere with the evaluation of the responses
Has a history of provider-diagnosed asthma requiring the use of medications at any age or has had a wheezing episode or use of medications to treat asthma in the 12 months prior to screening
Has immunosuppression as a result of an underlying illness or treatment, a recent history or current use of immunosuppressive or immunomodulating disease therapy
In the opinion of the site principal investigator or appropriate sub-investigator
Has a diagnosis of or history of malignant neoplastic disease
Has taken oral, parenteral (intramuscular or intravenous), inhaled, or nasal corticosteroids of any dose within 30 days prior to study vaccination
Has known HIV, hepatitis B, or hepatitis C infection
Has known hypersensitivity or allergy to any components of the study vaccine or material in the nasal delivery device
Has a history of severe reactions following previous immunization with licensed or unlicensed influenza vaccines
Has a history of an anatomic disorder of the nares or nasopharynx
Has a history of chronic sinus infections
Has a history of or currently smokes or vapes
Has a history of Guillain-Barré syndrome
Use of aspirin- or salicylate-containing products in the 30 days prior to or intends to use these products in the 30 days following administration of the investigational vaccine
Has a history of documented influenza or receipt of influenza antiviral treatment in the 4 months prior to the first vaccination
Vaccine components: sucrose, sodium chloride, phosphate, glutamate; delivery device material: polycarbonate, polypropylene, synthetic rubber
Receipt of any antiviral drug within the week prior to or following the investigational vaccine
Receipt of a licensed live vaccine within 30 days prior to the first study vaccination or plans to receive a licensed live vaccine within the 30 days after the last study vaccination
Receipt of licensed inactivated non-influenza vaccine within 14 days prior to the first study vaccination, or plans to receive licensed, inactivated vaccine within the 30 days after the last study vaccination. Participants will be asked to avoid receipt of any routine licensed vaccines or vaccines under emergency use authorization during the periods described
Receipt of an influenza vaccine within the 4 months prior to the first study vaccination or plans to receive an influenza vaccine following the last study vaccination. Seasonal IIV4 will be received by participants as part of this trial
Receipt of immunoglobulin or other blood products within the 6 months prior to the first study vaccination or plans to receive during the period of study participation
Receipt of an experimental agent or device within the 6 months prior to the first study vaccination or expects to receive an experimental agent or device during the study period
Products for treatment or prevention of coronavirus disease 2019 (COVID-19), when received under Emergency Use Authorization (EUA) or full FDA approval and not as part of a clinical trial, will not be deemed "experimental" for the purposes of this criterion and will not make an otherwise eligible prospective participant ineligible
Is a family member of study personnel or personnel directly involved in the conduct or monitoring of the study
Receipt of an approved or experimental product for treatment or prevention of COVID-19 within the 10 days prior to study enrollment
Participants may enroll if greater than 10 days after receipt of the COVID-19 treatment or prevention
Participants who are receiving COVID-19 vaccines around the time of dosing of the investigational product will be asked to avoid COVID-19 vaccination within the 10 days before any vaccination in the study and within any reactogenicity period (the day of and 7 days following each intranasal vaccination)
Inability of the study team to collect 5 mL of blood from the participant before the
first vaccination (pre-vaccination blood)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note